Cargando…

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approache...

Descripción completa

Detalles Bibliográficos
Autores principales:	Augello, Giuseppa, Modica, Martina, Azzolina, Antonina, Puleio, Roberto, Cassata, Giovanni, Emma, Maria Rita, Di Sano, Caterina, Cusimano, Antonella, Montalto, Giuseppe, Cervello, Melchiorre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833482/ https://www.ncbi.nlm.nih.gov/pubmed/29348495 http://dx.doi.org/10.1038/s41419-017-0195-0

Ejemplares similares

Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies
por: Emma, Maria Rita, et al.
Publicado: (2021)

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma
por: Suarez, Lorena P., et al.
Publicado: (2016)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
por: Augello, Giuseppa, et al.
Publicado: (2020)

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
por: Cervello, Melchiorre, et al.
Publicado: (2012)

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
por: Cervello, Melchiorre, et al.
Publicado: (2013)

Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta
por: Longo, Valeria, et al.
Publicado: (2020)

New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells
por: Augello, Giuseppa, et al.
Publicado: (2023)

Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
por: Cusimano, Antonella, et al.
Publicado: (2014)

MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma
por: Xu, Hao, et al.
Publicado: (2022)

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
por: Bondì, Maria Luisa, et al.
Publicado: (2014)

Correction to: Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
por: Di Gesù, Roberto, et al.
Publicado: (2018)

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
por: Liu, Wei, et al.
Publicado: (2017)

New landscapes and horizons in hepatocellular carcinoma therapy
por: Cervello, Melchiorre, et al.
Publicado: (2020)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

The clinical impact of an extra virgin olive oil enriched mediterranean diet on metabolic syndrome: Lights and shadows of a nutraceutical approach
por: Seidita, Aurelio, et al.
Publicado: (2022)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
por: Li, Haoyu, et al.
Publicado: (2016)

Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy
por: Aubry, Arthur, et al.
Publicado: (2020)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
por: Smith, David C., et al.
Publicado: (2015)

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
por: Harris, Michael A., et al.
Publicado: (2020)

The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods
por: Soresi, Maurizio, et al.
Publicado: (2020)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis
por: Wang, Hao, et al.
Publicado: (2016)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia
por: Sánchez, Gina, et al.
Publicado: (2020)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism
por: Chattopadhyay, Nibedita, et al.
Publicado: (2015)

2238. Effect of Cefazolin Breakpoint Update in Susceptibility Reports on Antimicrobial Use
por: Buckley, Valerie, et al.
Publicado: (2023)

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
por: Assouline, S E, et al.
Publicado: (2014)

The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases
por: Rubattu, Speranza, et al.
Publicado: (2018)

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance
por: Emma, M R, et al.
Publicado: (2016)

A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018)

Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population
por: Giannitrapani, Lydia, et al.
Publicado: (2022)

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
por: McCubrey, James A., et al.
Publicado: (2022)

Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)

Ixazomib-Associated Skin Exfoliation
por: Zhang, Yali, et al.
Publicado: (2022)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r7a7o46ddurcla4991onu4a0as